QUOZOVAMERAN
UNII B5TAS8B453

Substance Identification & Data

This profile provides standardized clinical and technical data for Quozovameran, uniquely identified by the FDA Unique Ingredient Identifier (UNII) B5TAS8B453.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 3047336-79-5 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code
B5TAS8B453
CAS Registry Number
3047336-79-5
RxNorm Concept ID
N/A

Detailed Substance Profile

Preferred Name
QUOZOVAMERAN
Official standardized name for this substance within the FDA UNII nomenclature system.
NCI Thesaurus
C223298
National Cancer Institute reference terminology for clinical and research data.
INN ID
13811
Sequential identifier assigned via the WHO International Nonproprietary Name program.
Substance Type
nucleicAcid
ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Quozovameran. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

QUOZOVAMERAN

Common Names & Synonyms

QUOZOVAMERAN [INN]
RNA (RECOMBINANT 5'-(M7G-(5'->5')-PPP-AM)-CAPPED VENEZUELAN EQUINE ENCEPHALITIS VIRUS NONSTRUCTURAL POLYPROTEIN CODON-OPTIMIZED GENE PLUS SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 SPIKE GLYCOPROTEIN (682-GLYCINE,683-SERINE,685-SERINE,986-PROLINE,987-PROLINE) OMICRON JN.1 VARIANT PRECURSOR CODON-OPTIMIZED GENE PLUS 5'- AND 3'-UNTRANSLATED FLANKING REGION-CONTAINING POLY(A)-TAILED MESSENGER MRNA-2425), INNER SALT
SELF-AMPLIFYING MESSENGER RNA (MRNA), 5'-CAPPED, ENCODING CODON-OPTIMISED VENEZUELAN EQUINE ENCEPHALITIS VIRUS (VEEV) RNA-DEPENDENT RNA POLYMERASE COMPLEX (VEEV PROTEINS NSP1, NSP2, NSP3 AND NSP4) AND A FULL-LENGTH CODON-OPTIMISED PRE-FUSION STABILISED CONFORMATION VARIANT (K982P AND V983P) OF THE SARS-COV-2 (SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2) SPIKE (S) GLYCOPROTEIN OMICRON VARIANT JN.1 (GISAID ENTRY: EPI_ISL_18872762) CONTAINING FURIN CLEAVAGE-INACTIVATING MUTATIONS (R678G, R679S AND R681S), FLANKED BY 5' AND 3' UNTRANSLATED REGIONS AND A 3' POLYADENYLATION (POLYA) TAIL; GENERATION OF CAPPED S GLYCOPROTEIN MRNA IS UNDER CONTROL OF A VEEV SUBGENOMIC PROMOTER

External Clinical & Regulatory Resources

CAS
Common Chemistry
NCATS
Inxight Drugs
NLM
DailyMed Products
NCATS
GSRS Full Record
NIH
NCI Thesaurus